Whalesbook
THE SEAMLESS LINK
This budgetary proposal extends a multi-year effort by the Indian government to enhance access to critical medicines. The core intention is to alleviate the financial burden associated with treating rare and life-threatening conditions, particularly for individuals who rely on imported pharmaceuticals. The move signals a continued policy direction towards supporting healthcare access through fiscal measures, though its ultimate impact on widespread affordability faces scrutiny.
Budgetary Relief for Specialized Pharmaceuticals
Finance Minister Nirmala Sitharaman's 2026 budget speech included a significant proposal to exempt import duties on seven specific drugs designated for rare diseases. These exemptions apply to personal imports of medicines and food for special medical purposes (FSMP) used in treating conditions such as congenital hyperinsulinemia hypoglycaemia, familial homozygous hypercholesterolemia, alpha mannosidosis, primary hyperoxaluria, cystinosis, hereditary angioedema, and primary immune deficiency disorders. Alongside these, the budget also mandates full duty waivers on 17 anti-cancer drugs. This initiative aims to directly reduce the cost burden for patients accessing these vital treatments.
The Affordability Paradox
Patient advocacy groups have largely welcomed the move. Archana Vashisht Panda, co-founder of the Cure SMA Foundation of India, acknowledged the proposal as a significant step, noting it provides considerable relief to individual patients purchasing medicines out-of-pocket. She estimated this relief could lower costs by approximately 10-15%. However, critics and some industry observers caution that duty cuts alone will not resolve the fundamental issue of prohibitively high base prices. The cost of many rare disease treatments can run into several lakhs or even crores of rupees, a factor the duty exemption does not alter.
Sectoral Context and Multinational Presence
This budgetary action aligns with a broader trend observed over the past three years, where the government has progressively reduced customs duties on many patented and imported anti-cancer and rare disease drugs. Global pharmaceutical corporations like Roche, GSK, Sanofi, and Novartis are principal suppliers of these highly specialized and often patented medications within the Indian market. Previous years have seen similar exemptions granted to drugs from companies such as AstraZeneca. These policy shifts aim to make advanced therapies more accessible in India.
Market Outlook and Access Challenges
The Indian pharmaceutical market continues its growth trajectory, with an increasing emphasis on complex generics, biologics, and specialized therapies. The current duty exemptions are a fiscal tool to address access barriers for specific high-cost drugs, potentially influencing import volumes and patient demand. While the reduction in landed cost is a positive development, the sector faces ongoing challenges in balancing innovation costs with the need for affordable healthcare solutions for a diverse population. The long-term success of such measures will depend on their ability to translate into sustainable affordability for a larger segment of patients.